Drug Trial Radar · NCT06599216
Adebrelimab Combined With Dalpiciclib and Standard Endocrine Therapy for HR + / HER2- Breast Cancer
Last checked: Nov 19, 2026Latest source record: Aug 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Oct 8, 2024
Primary completion
Mar 1, 2026
Study completion Sep 1, 2027
Sponsor
- Lead sponsor
- Harbin Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study intends to explore the efficacy and safety of PD-L1 inhibitor Adebrelimab combined with the CDK4/6 inhibitor Dalpcicilib and standard endocrine therapy given as neoadjuvant treatment in stages II-III hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer.
Conditions
- Breast Cancer
- HR+/HER2- Breast Cancer
Interventions
Adebrelimab+Dalpciclib+Standard Endocrine TherapyDrug
Adebrelimab: 1200mg, intravenously, Q4w Dalpiciclib: 150mg once a day for 3 weeks, stop for 1 week, Q4w Standard Endocrine Therapy: Choice of endocrine therapy is according to guidelines and centre policy by investigator
Primary outcomes
What the sponsor says the trial is designed to measure.
- tpCR rateTime frame: through study completion, an average of one and a half years
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Harbin Medical Cancer Hospital
Harbin, Heilongjiang, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.